## Discovery of Boron-conjugated 4-Anilinoquinazoline as a Prolonged Inhibitor of EGFR Tyrosine Kinase

Hyun Seung Ban,<sup>a</sup> Taikou Usui,<sup>a</sup> Wataru Nabeyama,<sup>a</sup> Hidetoshi Morita,<sup>b</sup> Kaori Fukuzawa,<sup>c</sup> and Hiroyuki Nakamura<sup>\*a</sup>

- a) Department of Chemistry, Faculty of Science, Gakushuin University, Mejiro, Toshima-ku, Tokyo 171-8588, Japan
- b) Graduate School of Science and Engineering, Yamagata University, Yamagata 990-8560, Japan
- c) Mizuho Information & Research Institute, Inc., Tokyo 101-8443, Japan

## 1. Molecular Docking and Quantum Mechanical Simulations



Fig. S1 QM/MM optimized geometries for an EGFR-compound 7d docking mode (model 1).



Fig. S2 QM/MM optimized geometries for an EGFR-compound 7d docking mode (model 2).



Fig. S3. QM/MM optimized geometries for an EGFR-compound 7d docking mode (model 3).

## 2. Additional *in vitro* irreversible inhibition study of EGFR tyrosine kinase activity

(A)



	ATP (uM)	EGFR Activity (%)	
		5 min	15 min
<b>7d</b> (100 nM)	10	$45.6 \pm 0.8$	$28.7 \pm 1.2$
	100	$57.1 \pm 9.8$	$32.3 \pm 1.6$
Tar (10 nM)	10	$27.0 \pm 3.6$	$24.7 \pm 4.9$
	100	$62.8 \pm 1.6$	61.9±8.6
PD (10 nM)	10	$34.9 \pm 5.7$	$16.8 \pm 4.9$
	100	$46.4 \pm 2.6$	$24.0 \pm 2.4$

**Fig. S4.** Effects of ATP concentration on *in vitro* preincubation-time-dependent EGFR inhibition by compound **7d**. EGFR was incubated in kinase assay buffer with 100 nM compound **7d**, 10 nM Tarceva (Tar), or 10 nM PD168393 (PD). After incubation for 5 and 15 min, kinase assay was initiated by adding 10  $\mu$ M ATP (A) or 100  $\mu$ M ATP (B), and phosphorylation of the poly(Glu:Tyr) substrate was detected. (C) Percent of EGFR activity represent mean±s.d.

## 3. <sup>1</sup>H NMR spectra for compounds 2-4



**Fig. S5.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **2**.



**Fig. S6.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound **3**.



Fig. S7. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of compound 4.